Yes, Carcinoid Tumors Are Hormone-Based
Carcinoid tumors are fundamentally hormone-producing neoplasms that arise from neuroendocrine cells and can secrete various hormones and vasoactive peptides, though not all tumors cause clinically apparent hormonal symptoms. 1, 2
Understanding Hormone Production in Carcinoid Tumors
Carcinoid tumors originate from neuroendocrine cells and have the inherent capacity to produce and secrete multiple bioactive substances:
Primary Hormones and Mediators Produced:
- Serotonin (5-hydroxytryptamine) - the predominant hormone
- Tachykinins
- Histamine
- Other vasoactive compounds 2, 3
Site-Specific Hormone Production:
Midgut and small intestine carcinoids produce significantly higher levels of serotonin and its breakdown products compared to foregut or hindgut tumors 4. This explains why these tumors more frequently cause carcinoid syndrome.
Bronchial and thymic carcinoids can produce ACTH, causing Cushing's syndrome, or GHRH, causing acromegaly 1, 5, 6.
Functional vs. Nonfunctional Tumors
This is a critical distinction: Patients with hormonal symptoms are classified as having "functional" tumors, while those without symptoms have "nonfunctional" tumors 1. However, this terminology is somewhat misleading—even "nonfunctional" tumors produce hormones, but either:
- The hormone levels are insufficient to cause symptoms
- The metabolic products are destroyed by liver enzymes before reaching systemic circulation 7, 2
The Carcinoid Syndrome
The classic carcinoid syndrome (flushing, diarrhea, cardiac involvement) occurs in only 8-28% of patients with carcinoid tumors 1, 7. This syndrome requires:
- Liver metastases (in most cases) - allowing hormones to bypass hepatic first-pass metabolism and enter systemic circulation directly via hepatic veins 2
- OR retroperitoneal disease (rarely) 7
Without liver metastases, the metabolic products from intestinal carcinoids are rapidly destroyed by liver enzymes in the portal circulation 7, 2.
Clinical Implications
Monitoring Requirements:
All patients require monitoring of circulating and urinary hormone levels during treatment 2. Specifically:
- 24-hour urinary 5-HIAA (5-hydroxyindoleacetic acid - serotonin breakdown product)
- Serum chromogranin A
- Additional hormones based on clinical syndrome (ACTH, cortisol, GHRH, IGF-1) 1
Treatment Targeting Hormone Production:
Somatostatin analogues are the only proven hormonal management for neuroendocrine tumors, working by inhibiting hormone release 2. These achieve:
- Biochemical response (inhibition of hormone production) in 30-70% of patients
- Symptomatic control in the majority of patients 2
Critical Perioperative Consideration:
Even patients with carcinoid tumors WITHOUT syndrome require increased somatostatin analogue coverage during stress (anesthesia, surgery, hepatic artery embolization) to prevent carcinoid crisis—a life-threatening release of massive hormone quantities 2. This underscores that hormone production is inherent to these tumors regardless of baseline symptoms.
Common Pitfall
Do not assume that absence of carcinoid syndrome means absence of hormone production. Somatostatin receptors are present in 70-95% of NETs 2, confirming their neuroendocrine nature even when clinically silent. The tumor's hormone-producing capacity remains a defining characteristic and therapeutic target regardless of symptomatology.